- Home
- JSPR vs RAND Comparison
JSPR vs RAND Comparison
Compare JSPR & RAND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JSPR | RAND |
|---|---|---|
| Founded | 2018 | 1969 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.7M | 41.2M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | JSPR | RAND |
|---|---|---|
| Price | $1.55 | $11.39 |
| Analyst Decision | Buy | |
| Analyst Count | 10 | 0 |
| Target Price | ★ $18.13 | N/A |
| AVG Volume (30 Days) | ★ 975.8K | 6.3K |
| Earning Date | 02-26-2026 | 03-09-2026 |
| Dividend Yield | N/A | ★ 10.31% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $7,327,287.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.39 | $10.56 |
| 52 Week High | $7.19 | $31.89 |
Technical Indicators
Market Signals| Indicator | JSPR | RAND |
|---|---|---|
| Relative Strength Index (RSI) | 43.80 | 42.28 |
| Support Level | $1.51 | $11.00 |
| Resistance Level | $1.66 | $12.50 |
| Average True Range (ATR) | 0.12 | 0.33 |
| MACD | 0.00 | 0.08 |
| Stochastic Oscillator | 45.19 | 26.00 |
Price Performance
Historical ComparisonAbout JSPR Jasper Therapeutics Inc.
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.
About RAND Rand Capital Corporation
Rand Capital Corp is a closed-end, externally managed, non-diversified investment company. The company's investment objective is to generate current income and, when possible, complement its current income with capital appreciation by focusing its debt and related equity investments in privately-held, lower middle market companies with committed and experienced managements in a broad variety of industries. It predominantly invests in higher-yielding debt instruments.